CA2382216A1 - Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale - Google Patents

Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale Download PDF

Info

Publication number
CA2382216A1
CA2382216A1 CA002382216A CA2382216A CA2382216A1 CA 2382216 A1 CA2382216 A1 CA 2382216A1 CA 002382216 A CA002382216 A CA 002382216A CA 2382216 A CA2382216 A CA 2382216A CA 2382216 A1 CA2382216 A1 CA 2382216A1
Authority
CA
Canada
Prior art keywords
drugs
mixture
salbutamol
spray dried
ipratropium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382216A
Other languages
English (en)
Inventor
Xian Ming Zeng
Austen John Woolfe
Alan Langford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of CA2382216A1 publication Critical patent/CA2382216A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation pharmaceutique comprenant un mélange de deux médicaments éventuellement associés à un ou plusieurs excipients, ledit mélange étant obtenu par: co-cristallisation ou co-précipitation des médicaments, puis par micronisation ou broyage, de manière à produire une poudre uniforme ayant une granulométrie et autres propriétés appropriées pour constituer une formulation destinée à être administrée par voie pulmonaire ou nasale.
CA002382216A 1999-08-20 2000-08-21 Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale Abandoned CA2382216A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15009599P 1999-08-20 1999-08-20
US60/150,095 1999-08-20
PCT/GB2000/003230 WO2001013885A1 (fr) 1999-08-20 2000-08-21 Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale

Publications (1)

Publication Number Publication Date
CA2382216A1 true CA2382216A1 (fr) 2001-03-01

Family

ID=22533110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382216A Abandoned CA2382216A1 (fr) 1999-08-20 2000-08-21 Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale

Country Status (4)

Country Link
JP (1) JP2003526629A (fr)
AU (1) AU6852900A (fr)
CA (1) CA2382216A1 (fr)
WO (1) WO2001013885A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
EP1992335A1 (fr) 2001-11-01 2008-11-19 Nektar Therapeutics Procédés de séchage par pulvérisation et compositions correspondantes
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
FI20020857A (fi) * 2002-05-07 2003-11-08 Focus Inhalation Oy Amorfisen aineen muuntaminen vastaavaksi kiteiseksi aineeksi spraykuivaamalla ja käyttämällä kiteistä spraykuivattua ainetta lääkevalmisteissa
EP1531866A1 (fr) * 2002-08-29 2005-05-25 Cipla Ltd. Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
EP1646354A4 (fr) * 2003-07-22 2010-03-17 Baxter Int Petites particules spheriques de molecules organiques de faible poids moleculaire et procedes de preparation et d'utilisation correspondants
EP1976486A1 (fr) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Procede de production de microparticules poreuses
WO2007134965A1 (fr) * 2006-05-19 2007-11-29 Boehringer Ingelheim International Gmbh Formulation d'aérosol contenant du bromure d'ipratropium et du sulfate de salbutamol
CA2652699C (fr) 2006-05-19 2014-11-04 Boehringer Ingelheim International Gmbh Formulation d'aerosol sans gaz propulseur destinee a etre inhalee, contenant du bromure d'ipratropium et du sulfate de salbutamol
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239B1 (fr) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adaptateur, dispositif d'inhalation et pulvérisateur
WO2011064164A1 (fr) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nébuliseur
EP2504051B1 (fr) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nébuliseur
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011160932A1 (fr) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nébuliseur
EP2694220B1 (fr) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Appareil médical pourvu d'un récipient
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
EP2835146B1 (fr) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Atomiseur
EP3030298B1 (fr) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nébuliseur
EA032459B1 (ru) 2014-05-07 2019-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Небулайзер
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
PL3139979T3 (pl) 2014-05-07 2023-12-27 Boehringer Ingelheim International Gmbh Jednostka, nebulizator i sposób
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
EP0969816B1 (fr) * 1997-03-20 2004-12-15 Schering Corporation Preparation d'agglomerats de poudre
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation

Also Published As

Publication number Publication date
AU6852900A (en) 2001-03-19
JP2003526629A (ja) 2003-09-09
WO2001013885A1 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
CA2382216A1 (fr) Procede de production de poudres destinees a etre administrees par voie pulmonaire ou nasale
US20020081266A1 (en) Spray dried powders for pulmonary or nasal administration
EP2560620B1 (fr) Procédé de traitement de particules de principes actifs pharmaceutiques
RU2148992C1 (ru) Способ кондиционирования веществ
Dhumal et al. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery
JP7110303B2 (ja) ピリミド［６，１－ａ］イソキノリン－４－オン化合物の塩
SK95999A3 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
Corrigan et al. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers
AU2008334547B2 (en) Organic compounds
SK284919B6 (sk) Spôsob výroby práškových aglomerátov a dávková forma s ich obsahom
CN1430508A (zh) 新的组合物
CA2910314C (fr) Reduction de la taille de particule d'un compose antimuscarinique
US6641063B2 (en) Milling process for the production of finely milled medicinal substances
MXPA05006519A (es) Medicamentos en polvo para inhalacion que contienen una sal de tiotropio y salmeterolxinafoato.
JP6940416B2 (ja) 多剤脆性マトリックス組成物
PL199420B1 (pl) Medyczne preparaty aerozolowe
US20060002864A1 (en) Milling process for the production of finely milled medicinal substances
US20100247658A1 (en) Organic compounds
CN106604720A (zh) 包含格隆铵的制剂、方法和设备
AU754074B2 (en) A method for making a pharmaceutical formulation

Legal Events

Date Code Title Description
FZDE Dead